Cronos Australia Ltd. (VIT) AI Stock Analysis

• Market Cap: AU$27.17M
• Dividend Yield: 3.28%
• Average Volume (3M): 228.84K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.70
• Revenue Growth: 0.13%
• EPS Growth: -12.90%
• Country: AU
• Employees: 72
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 662,741,800
• 10 Day Avg. Volume: 238,134
• 30 Day Avg. Volume: 228,844
• PEG Ratio: -1.01
• Price to Book (P/B): 0.78
• Price to Sales (P/S): 0.30
• P/FCF Ratio: 14.63
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: AU$0.04 ▼(-36.67% Downside)
• Action: Reiterated Date: 03/05/26
• Date: Action: Reiterated 03/05/26

The score is held up by a relatively stable balance sheet and shareholder yield, but it is dragged down by weak cash-flow trends and a clearly bearish technical setup with price below key moving averages and negative MACD.

Positive Factors

Balance-sheet conservatism

Low leverage and a high equity ratio give Cronos Australia durable financial flexibility. A conservative capital structure reduces refinancing and interest risks, supporting multi-quarter resilience for R&D, regulatory timelines, or working-capital needs without forcing distress asset sales.

Negative Factors

Revenue decline

Declining top-line indicates demand, pricing, or product-mix headwinds. Sustained revenue erosion reduces scale, compresses fixed-cost absorption, and limits ability to fund R&D or marketing internally, challenging growth prospects over the next several quarters without strategic changes.

Cronos Australia Ltd. Business Overview & Revenue Model

Company Description

Vitura Health Limited engages in the sale and distribution of medicinal cannabis products in Australia and Asia. Its brands include CanView, Burleigh Heads Cannabis, CDA Clinics, Cannadoc, and Adaya. The company was formerly known as Cronos Austra...

Read more

Vitura Health Limited engages in the sale and distribution of medicinal cannabis products in Australia and Asia. Its brands include CanView, Burleigh Heads Cannabis, CDA Clinics, Cannadoc, and Adaya. The company was formerly known as Cronos Austra...

How the Company Makes Money

null...

Cronos Australia Ltd. Financial Statement Overview

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	129.24M	124.04M	123.87M	117.34M	66.99M	21.71M
Gross Profit	19.87M	33.75M	34.22M	25.96M	25.43M	3.19M
EBITDA	4.15M	5.64M	7.08M	21.08M	10.87M	2.12M
Net Income	784.13K	3.32M	3.51M	13.81M	6.05M	-4.05M
Balance Sheet
Total Assets	76.85M	75.49M	71.28M	46.90M	42.87M	12.69M
Cash, Cash Equivalents and Short-Term Investments	6.10M	7.58M	11.35M	18.85M	16.08M	9.47M
Total Debt	17.34M	11.97M	11.02M	1.71M	5.06M	718.02K
Total Liabilities	31.49M	27.89M	32.84M	11.99M	16.79M	3.47M
Stockholders Equity	46.11M	48.20M	38.78M	34.98M	26.10M	9.30M
Cash Flow
Free Cash Flow	1.38M	2.58M	6.21M	8.78M	13.13M	1.01M
Operating Cash Flow	1.48M	2.67M	7.00M	9.71M	13.50M	1.07M
Investing Cash Flow	-4.95M	-13.87M	-13.20M	-837.72K	2.00M	-160.69K
Financing Cash Flow	2.18M	7.43M	-1.30M	-6.10M	-1.50M	-262.03K

Cronos Australia Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:VIT, the sentiment is Negative. The current price of 0.06 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.05, and above the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 36.55 is Neutral, neither overbought nor oversold. The STOCH value of 75.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:VIT.

Cronos Australia Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIT	57 Neutral	AU$27.17M	-12.06	1.66%	3.28%	0.13%	-12.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EXL	48 Neutral	AU$2.90M	-0.42	-76.30%	―	36.60%	85.28%
EPN	42 Neutral	AU$8.17M	172.12	649.03%	―	-1.25%	-188.33%
CAN	39 Underperform	AU$9.58M	0.07	93.89%	―	-26.49%	61.72%

Cronos Australia Ltd. Corporate Events